AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02541877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Down sizing valve in type-0 BAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
Study NCT02541877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sizing valve in type-0 BAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
Study NCT02541877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sizing valve in TAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
Study NCT01004848 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-Led Lifestyle Education on Weight Loss
Description: Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
Study NCT01004848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Lifestyle Education on Weight Loss
Description: Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
Study NCT00981617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (10 mg)
Description: 10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study NCT00981617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily for 12 weeks
Study NCT01092468 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diathermy
Description: flap dissection with conventional diathermy
Study NCT01092468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic Scalpel
Description: flap dissection using harmonic scalpel (FOCUS)
Study NCT03150043 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo Rainbow Pulse CO-oximeter
Description: Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
Study NCT03650153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-rectal MRI targeted Biopsy
Description: Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
Study NCT03650153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-perineal MRI targeted Biopsy
Description: Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
Study NCT01859988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study NCT01859988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04350593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 milligram (mg)
Description: Active Comparator: Dapagliflozin 10 mg
Study NCT04350593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT03484169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;
Study NCT01851993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study NCT01851993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT01855022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + IVR
Description: Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
Study NCT03346239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze Contingent Music Reward Therapy
Description: Feedback according to participants' viewing patterns, in order to modify their attention.
Study NCT03346239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg of Escitalopram
Study NCT03346239 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
Study NCT01317940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium Citrate
Description: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months
Study NCT04670601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Test 8.75 MG
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Study NCT04670601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Reference 8.75 MG
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Study NCT02976883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]HX4 diagnostic PET/CT scan
Description: Single intravenous injection of \[18F\]HX4 and PET/CT scan
Study NCT02990000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scientific Match
Description: We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
Study NCT04127370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
Study NCT01912976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL-PDT
Description: Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Study NCT01912976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL-PDT
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Study NCT03246464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology lenses
Description: Rigid gas permeable contact lenses
Study NCT03246464 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision spectacles
Description: Regular single vision spectacles
Study NCT01183364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib) with Docetaxel
Description: One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
Study NCT01477801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOLECALCIFEROL
Description: Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months
Study NCT01477801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Standard guideline based therapy plus placebo
Study NCT00869414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening only administration of insulin glargine
Description: Evening only administration of insulin glargine, with normal saline injection administered in the morning.
Study NCT00869414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morning only administration of insulin glargine
Description: Morning only administration of insulin glargine, with normal saline injection administered at night.
Study NCT00869414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: split dose insulin glargine
Description: split dose of insulin glargine, half administered in the morning, half administered in evening
Study NCT01460303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag
Description: OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter).
Study NCT01460303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral catheter with leg bag
Description: Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter).
Study NCT04006145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat
Description: Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
Study NCT04006145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo identical in appearance to active drug
Study NCT00956436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB022
Description: IV Q3W
Study NCT00956436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard dosing of Sorafenib
Study NCT02887703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Augmentation
Description: Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
Study NCT03566225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Insulin sensitizing agents
Study NCT03566225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Insulin sensitizing agent
Study NCT03566225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Induction drug
Study NCT03546400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methylphenidate HCl ERCT
Description: methylphenidate HCl ERCT
Study NCT01631227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Eprosartan 450 mg
Study NCT01631227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprosartan Mesylate
Description: Eprosartan mesylate 600 mg
Study NCT01631227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eprosartan mesylate
Description: Placebo Eprosartan mesylate
Study NCT01631227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Eprosartan
Description: Placebo Eprosartan
Study NCT02822859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wright nebulizer
Description: Roxon Medi-Tech, Montreal, QC, Canada
Study NCT02822859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bennett-Twin nebulizer
Description: Puritan Bennett Corp., Carlsbad, CA, USA
Study NCT02822859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb Solo
Description: Aerogen Ltd., Galway, Ireland
Study NCT02751541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Sport Spray (BAY987519)
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
Study NCT02751541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control.
Study NCT01177800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
Study NCT01177800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
Study NCT04848701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: latent phase duration
Description: latent phase duration in post term pregnancies
Study NCT04848701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: uterocervical angle (UCA)
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study NCT03871673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweet manioc starch
Description: 100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
Study NCT03871673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cornstarch
Description: 100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
Study NCT02321332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral simultaneous endoscopic thoracic symapthectomy
Description: Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
Study NCT02321332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral sequential endoscopic thoracic symapthectomy.
Description: Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
Study NCT01917721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
Study NCT01917721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
Study NCT00405366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sorafenib tosylate
Description: Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
Study NCT02920489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized epidural analgesia
Description: Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
Study NCT02920489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine epidural analgesia
Description: Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
Study NCT02625688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
Study NCT02625688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord milking
Description: If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
Study NCT02625688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Early cord clamping
Description: We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
Study NCT00580242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study NCT00580242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study NCT00580242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study NCT00580242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period